Navigation Links
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced encouraging results in an ongoing Dana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. To date, 10 patients were evaluable for best overall tumor response (assessed at least after 8 weeks / 2 chemotherapy cycles), whereby all 10 women had previously failed three lines of chemotherapy (starting fourth line). 1 patient had a partial response, 5 stable disease and 4 progressive disease. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies.

The primary objective of this open-label single-arm Phase 2 is to determine the tumor response rate in a cohort of women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin. Up to 25 women may be enrolled in the trial and may receive up to six cycles of NOV-002 and carboplatin. A link to the trial description and contact information is available at www.novelos.com under 'Clinical Trials' section.

"I am encouraged by these preliminary results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the treated patients," said Dr. Carolyn Krasner, the Principal Investigator. "Most women, having failed three lines of chemotherapy, would be expected to progress in about eight weeks."

"We look forward to continuing to work closely with Dana-Farber/Partners on developing NOV-002 for this indication," said Harry Palmin, President and CEO of Novelos. "Meanwhile, Novelos remains on-track for full enrollment of our pivotal Phase 3 trial of NOV-002 for lung cancer in the first quarter 2008."

Acco
'"/>




Page: 1 2 3

Related medicine technology :

1. Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
(Date:8/20/2014)... ApolloDx™ today announced it will unveil and ... event at the company,s office in Salt ... The event, which will start at 10:00 a.m., will ... .    "We believe our mobile diagnostic ... , Co-Founder and Managing Partner of ApolloDx. In addition ...
(Date:8/20/2014)... Trovagene, Inc. (NASDAQ:   TROV), a developer ... two clinical studies will be presented at the 29th ... test for the detection of high risk strains of ... take place in Seattle from ... a new U.S. patent was issued earlier this year ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... Feb. 15, 2011 Pfenex Inc., an industry ... Technology™ platform and Boehringer Ingelheim International GmbH, a ... contract development and manufacture, announced today that they ... Boehringer Ingelheim with non-exclusive access to the Pfenex ...
... Vermillion, Inc. (Nasdaq: VRML ), a ... to sell 4,000,000 shares of its common stock in ... per share.  The Company expects that the net proceeds ... underwriting discounts and expected offering expenses.  The Company intends ...
Cached Medicine Technology:Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 3Vermillion Announces $21.8 Million Public Offering 2Vermillion Announces $21.8 Million Public Offering 3Vermillion Announces $21.8 Million Public Offering 4
(Date:8/20/2014)... Steven Reinberg HealthDay Reporter ... at which cancer cells grow may help doctors diagnose and ... this measure, investigators have found that the deadliest skin cancers ... men with a long history of sun exposure. These ... discovered. Rapid cell growth -- called "high mitotic ...
(Date:8/20/2014)... 20, 2014 Park Cities Pet Sitter ... Presents 4 Pets supply donation drive that benefits the animal ... national campaign that coincides with the Humane Society of the ... 2nd through 8th, 2014. , As part of their participation, ... and monetary donations for the Presents 4 Pets drive from ...
(Date:8/20/2014)... salmon that sprint to spawning grounds through fast-moving waters ... of British Columbia scientists. , When salmon encounter turbulent, ... of dams they must move upstream using a ... sprinting for humans. , "Days after sockeye passed through ... only a short distance from their spawning grounds," said ...
(Date:8/20/2014)... novel approach to treating cancer - using Botox. A ... Science Translational Medicine shows that cancer growth could ... that are linked to cancer stem cells. The approach ... the treatment cheap, safe and efficient. The researchers have ... soon start testing on humans. , The nervous system ...
(Date:8/20/2014)... stimulates stress responses in adults, researchers at Yerkes ... that the amygdala has an inhibitory effect on ... primates. , The results are published this week ... amygdala is a region of the brain known ... and learning about threats. Alterations in the amygdala ...
Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Treating gastric cancer -- with Botox 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... , , , BETHESDA, Md., ... Interactive Patient Care (IPC) solutions, today announced the release of the ... bedside system includes tools focused on accelerating the discharge planning process ... , , "We are excited about ...
... WILMINGTON, Del., July 15 Caregivers of children under ... to determine if their child,s breathing problems are not under ... for Respiratory and Asthma Control in Kids, or TRACK, the ... under five years of age. TRACK helps evaluate respiratory control ...
... LUBBOCK, Texas, July 15 Trends in the economy and ... positions and more temporary assignments. This matches perfectly with an increasing ... their careers. For these reasons and more, Advantage Medical Staffing, ... to their moving to a larger location. , ...
... , FORT LAUDERDALE, Fla. and GRAND PRAIRIE, Texas, July 15 ... Charles Hill has joined the company,s distribution network to help ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090608/LIVETHESOURCELOGO ... sales expert, Hill will boost li vethesource (TM),s ...
... , , , Go to www.cncb.org ... , DALLAS, July 15 The following information on the CNCB Post Graduate ... , , Session I -Optimal Human Nutrition ... Essential Vitamins , Biochemistry of Essential Minerals , ...
... , , , ... /PRNewswire-USNewswire/ -- TrailBlazer Health Enterprises, LLC ... contract by the federal Centers for Medicare & Medicaid Services ... Jurisdiction 7, which includes Arkansas, Louisiana and Mississippi. The full ...
Cached Medicine News:Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 2Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 3Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 4Health News:New Five-Question Test Helps Assess Asthma Control in Children Under Five Years of Age 2Health News:New Five-Question Test Helps Assess Asthma Control in Children Under Five Years of Age 3Health News:New Five-Question Test Helps Assess Asthma Control in Children Under Five Years of Age 4Health News:Demand for Short-Term Medical Help Leads to Growth for Travel Nursing Staffing Agency; Prompts Move to New Location and Addition of New Online Tools for Nurses 2Health News:livethesource(TM), the World's First and Only Patented, Fully Nano-Encapsulated Liquid Vitamin, Mineral and Herbal Supplement, Now Available in Dallas Area 2Health News:livethesource(TM), the World's First and Only Patented, Fully Nano-Encapsulated Liquid Vitamin, Mineral and Herbal Supplement, Now Available in Dallas Area 3Health News:CNCB Post Graduate Studies in Clinical Nutrition (PGSCN) Program is Now Available Online 2Health News:CMS Selects TrailBlazer Health Enterprises to Administer Medicare Program in Arkansas, Louisiana and Mississippi 2
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
... balance. Built-in, motor-driven internal calibration mass ... Automatic Self-Calibration when temperature change detected ... Menu-selected weighing parameters, plug-in peripherals, and ... make this balance series highly accurate ...
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
Medicine Products: